Tino F. Schwarz, Prof. Dr. MD

Klinikum Würzburg Mitte, Campus Juliusspital, Würzburg, Germany, Germany

Disclosure(s): Biogen, Merck-Serono, Pfizer, Alexion, Bavarian Nordic, Janssen-Cilag, AstraZeneca, Biontech, MSD: Grants; GlaxoSmithKline Biologicals SA: Honoraria

Poster(s):

• 96 - A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET

• 119 - Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET